Medicine
Vyxeos 100 mg/44 mg per 20 mL powder for injectable suspension
Vyxeos 100 mg/44 mg per 20 mL powder for injectable suspension is a prescription medicine containing Cytarabine and Daunorubicin for intravenous use, marketed by Jazz Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unreconstituted VYXEOS vials in a refrigerator at 2°C to 8°C (36°F to…
Key facts
- Active ingredient (INN)
- Cytarabine and Daunorubicin
- Brand
- Vyxeos
- Strength
- 100 mg/44 mg per 20 mL
- Dosage form
- Powder for injectable suspension
- Route
- Intravenous
- Packs
- 20 mL, 40 mL
- Marketing authorisation holder
- Jazz Pharmaceuticals
- Manufacturer
- Jazz Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store unreconstituted VYXEOS vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in an upright position. The vial should be stored in its original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XY01 Cytarabine and Daunorubicin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 August 2017
- Identifiers
- RxCUI 1942743, 1942748DailyMed set ID 7ea701ce-e7d3-4349-a9c2-642a501d45c8NDC 68727-745Application NDA209401
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 20 mL in 1 vial | 68727-745-01 | Jazz Pharmaceuticals | 3 August 2017 |
| 40 mL in 1 carton | 68727-745-02 | Jazz Pharmaceuticals | 3 August 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Cytarabine and Daunorubicin is a fixed-dose combination of an anthracycline topoisomerase inhibitor and a nucleoside metabolic inhibitor. It is available as powder for injectable suspension for intravenous use. MedsAcross supplies Cytarabine and Daunorubicin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Cytarabine and DaunorubicinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- VYXEOS prescribing information (Jazz Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Vyxeos liposomal (previously Vyxeos): European public assessment report (EPAR) · European Medicines Agency
Need Vyxeos 100 mg/44 mg per 20 mL powder for injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.